NCT00774462 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis


Sponsors: Assistance Publique - Hôpitaux de Paris Institut National de la Santé Et de la Recherche Médicale, France Roche Pharma AG	Phases: Phase II
Indications	Acronym: FORCE
Myositis Myasthenia Gravis
Age Groups: Adult Senior	Gender: Both
Names: Drug: Rituximab	Enrollment: 36

Additional information about NCT00774462.